English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Friday, September 8, 2017
Conclusion of Development Collaboration Agreement for Lenvima (Lenvatinib Mesylate) and Opdivo (Nivolumab) Combination Therapy for Treatment of Hepatocellular Carcinoma
Wednesday, September 6, 2017
Eisai Signs Agreement with Merck & Co. to Expand Enrollment of Study for Halaven (Eribulin) and Pembrolizumab Combination Due to Encouraging Initial Data in Triple-Negative Breast Cancer
Eisai Signs Agreement with Merck & Co. to Expand Enrollment of Combination Study for Lenvima (Lenvatinib) and Pembrolizumab Due to Encouraging Initial Data in Endometrial Carcinoma
Friday, September 1, 2017
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO 2017 Congress Three Abstracts on Lenvima (Lenvatinib) to be Presented in Oral Session
Thursday, July 27, 2017
U.S. FDA Approves Additional Use of Antiepileptic Drug Fycompa as Monotherapy for Partial-Onset Seizures
Wednesday, July 26, 2017
Eisai Submits Simultaneous Applications in The United States and Europe for Lenvatinib in Hepatocellular Carcinoma
Tuesday, July 4, 2017
Wellness Open Living Labs. LLC, Co-Founded by Eisai and Osaka City University Conclude Basic Collaboration Agreement Aimed at Solving Health Problems
Wednesday, June 28, 2017
Eisai Listed for 16th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment
Tuesday, June 27, 2017
Eisai Temporarily Withdraws New Drug Application for Anticancer Agent Halaven in China
Friday, June 23, 2017
Eisai Submits Application for Additional Indication of Anticancer Agent Lenvima for Hepatocellular Carcinoma in Japan

Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575